Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval

Regeneron Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Regeneron reported strong third-quarter results: Revenue rose 36% year over year to about $5.1 billion, while adjusted EPS increased roughly 70% to just over $20. DUPIXENT, EYLEA HD and LIBTAYO were key contributors.
  • The company expects an EYLEA HD prefilled syringe to gain U.S. approval by year-end and potentially boost adoption. A patent review is underway, with a decision expected by early March 2027; Regeneron says other patents may support exclusivity into the late 2030s or 2040s.
  • Regeneron expects continued growth from its major products but plans higher R&D spending and investment to launch cemdisiran, which may weigh on near-term operating leverage. Executives also cited pipeline opportunities and said the company remains open to external deals while disciplined on valuation.
  • MarketBeat previews top five stocks to own in December.

Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.

Chief Financial Officer Chris Fenimore said third-quarter revenue was approximately $5.1 billion, up 36% from a year earlier. Adjusted earnings per share were just over $20, an increase of about 70%.

EYLEA HD generated approximately $700 million in the quarter, while cancer drug LIBTAYO recorded about $550 million in global sales, Fenimore said. Global sales of DUPIXENT were approximately $6.5 billion, including about $5 billion in the United States.

Fenimore said Regeneron fully repaid an approximately $3 billion development balance associated with the DUPIXENT alliance in the second quarter. The company saw the full benefit in the third quarter and expects to benefit again in the fourth quarter, as well as in year-over-year comparisons for the first two quarters of 2027.

EYLEA HD Outlook and Patent Review

Fenimore said the branded eye-care market has stabilized after copay assistance constraints affected patients beginning in 2025, although affordability challenges remain. He expects the overall market to grow at a low-single-digit rate, supported by an aging population and diagnoses of diabetic retinal disease.

Regeneron remains optimistic about securing U.S. approval for an EYLEA HD prefilled syringe by year-end, Fenimore said. He expects the device to provide an additional boost to adoption, though he said it was difficult to estimate its magnitude. Some providers have indicated they are waiting for the syringe before using the drug more broadly in their practices.

Ryan Crowe, senior vice president of investor relations and strategic analysis, said oral arguments in a post-grant review of an EYLEA HD patent are scheduled for Dec. 4, with a decision due by early March 2027. Crowe said Regeneron declined an offer from Alvotech to mutually withdraw the review and believes its case for the patent’s validity is compelling.

Crowe said other issued or pending patents could support EYLEA HD exclusivity into the late 2030s or the 2040s. He added that the company could not provide certainty about when biosimilars might launch.

Spending and Business Development

Fenimore declined to provide financial guidance but said Regeneron expects its major products to drive further top-line growth. He noted that the company had previously projected a mid-teens percentage increase in research and development investment year over year, which would affect operating leverage in the short term.

The planned launch of cemdisiran for myasthenia gravis, a new specialty neurology area for Regeneron, will also require selling, general and administrative investment, he said.

On acquisitions, Fenimore said the company is open to external deals but remains disciplined on valuation. He also said Regeneron believes its internal pipeline can diversify revenue and support growth around the turn of the decade. Under its expanded alliance with Sanofi, the companies could consider joint external opportunities, although they would assess them individually, he said.

Pipeline Plans

Executives highlighted early-stage opportunities in liver disease, ovarian cancer and postural orthostatic tachycardia syndrome, or POTS.

For its CIDEB program, Regeneron plans a one-year Phase 2b study with a primary endpoint measuring liver fat reduction at week 26 and biopsy data at week 52 assessing fibrosis and MASH resolution, Crowe said. The company intends to discuss the study design with the Food and Drug Administration, including whether a noninvasive endpoint could be incorporated.

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines